

Thomas F LÃ¼scher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4913648/publications.pdf>

Version: 2024-02-01

491
papers

19,883
citations

13099

68
h-index

15266

126
g-index

497
all docs

497
docs citations

497
times ranked

24430
citing authors

#	ARTICLE	IF	CITATIONS
1	Methylation of the Hippo effector YAP by the methyltransferase SETD7 drives myocardial ischaemic injury: a translational study. <i>Cardiovascular Research</i> , 2023, 118, 3374-3385.	3.8	10
2	Smoking Cessation in People With and Without Diabetes After Acute Coronary Syndrome. <i>Nicotine and Tobacco Research</i> , 2023, 25, 58-65.	2.6	2
3	Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. <i>European Heart Journal</i> , 2022, 43, 940-958.	2.2	8
4	Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 186-196.	3.3	8
5	Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology. <i>Cardiovascular Research</i> , 2022, 118, 2085-2102.	3.8	23
6	Artificial intelligence: the pathway to the future of cardiovascular medicine. <i>European Heart Journal</i> , 2022, 43, 556-558.	2.2	3
7	Vascular endothelial tissue factor contributes to trimethylamine N-oxide-enhanced arterial thrombosis. <i>Cardiovascular Research</i> , 2022, 118, 2367-2384.	3.8	45
8	MMP-2 knockdown blunts age-dependent carotid stiffness by decreasing elastin degradation and augmenting eNOS activation. <i>Cardiovascular Research</i> , 2022, 118, 2385-2396.	3.8	14
9	TNF α induces endothelial dysfunction in rheumatoid arthritis via LOX-1 and arginase 2: reversal by monoclonal TNF α antibodies. <i>Cardiovascular Research</i> , 2022, 118, 254-266.	3.8	13
10	Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy. <i>European Heart Journal</i> , 2022, 43, 683-697.	2.2	76
11	Dietary alpha-linolenic acid reduces platelet activation and collagen-mediated cell adhesion in sickle cell disease mice. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 375-386.	3.8	6
12	Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial. <i>American Heart Journal</i> , 2022, 247, 33-41.	2.7	8
13	Microvesicles released from activated CD4 ⁺ T cells alter microvascular endothelial cell function. <i>European Journal of Clinical Investigation</i> , 2022, , e13769.	3.4	3
14	Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 611-621.	3.0	10
15	Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts premature death in acute coronary syndromes. <i>European Heart Journal</i> , 2022, 43, 1849-1860.	2.2	28
16	Inflammation, Aging, and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2022, 79, 837-847.	2.8	113
17	The BET Protein Inhibitor Apabetalone Rescues Diabetes-Induced Impairment of Angiogenic Response by Epigenetic Regulation of Thrombospondin-1. <i>Antioxidants and Redox Signaling</i> , 2022, 36, 667-684.	5.4	15
18	Twitter promotion is associated with higher citation rates of cardiovascular articles: the ESC Journals Randomized Study. <i>European Heart Journal</i> , 2022, 43, 1794-1798.	2.2	19

#	ARTICLE	IF	CITATIONS
19	OUP accepted manuscript. Cardiovascular Research, 2022, , .	3.8	0
20	Rapid Inflammasome Activation Is Attenuated in Post-Myocardial Infarction Monocytes. Frontiers in Immunology, 2022, 13, 857455.	4.8	3
21	Assessment and pathophysiology of microvascular disease: recent progress and clinical implications. European Heart Journal, 2021, 42, 2590-2604.	2.2	74
22	Sirtuin 5 promotes arterial thrombosis by blunting the fibrinolytic system. Cardiovascular Research, 2021, 117, 2275-2288.	3.8	13
23	Extracellular vesicle species differentially affect endothelial cell functions and differentially respond to exercise training in patients with chronic coronary syndromes. European Journal of Preventive Cardiology, 2021, 28, 1467-1474.	1.8	11
24	Targeting cardiovascular inflammation: next steps in clinical translation. European Heart Journal, 2021, 42, 113-131.	2.2	186
25	Deletion of fibroblast activation protein provides atheroprotection. Cardiovascular Research, 2021, 117, 1060-1069.	3.8	20
26	Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of five contemporary European registries. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 94-103.	3.0	13
27	Prognostic value of total testosterone levels in patients with acute coronary syndromes. European Journal of Preventive Cardiology, 2021, 28, 235-242.	1.8	7
28	Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease. European Heart Journal, 2021, 42, 1797-1807.	2.2	58
29	Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines. European Journal of Preventive Cardiology, 2021, 28, 59-65.	1.8	30
30	Inflammation and cardiovascular diseases: lessons from seminal clinical trials. Cardiovascular Research, 2021, 117, 411-422.	3.8	59
31	They eat, what we eat, they digest, what we ingest: the microbiome and the vulnerable plaque. Cardiovascular Research, 2021, 117, 333-335.	3.8	1
32	Impact of malignancy on clinical outcomes in patients with acute coronary syndromes. International Journal of Cardiology, 2021, 328, 8-13.	1.7	5
33	Epigenetic Remodeling in Obesity-Related Vascular Disease. Antioxidants and Redox Signaling, 2021, 34, 1165-1199.	5.4	19
34	An exosomal-carried short periostin isoform induces cardiomyocyte proliferation. Theranostics, 2021, 11, 5634-5649.	10.0	19
35	Wine, chocolate, and coffee: forbidden joys?. European Heart Journal, 2021, 42, 4520-4522.	2.2	4
36	The Omega-3 Fatty Acid Eicosapentaenoic Acid (EPA) Correlates Inversely with Ischemic Brain Infarcts in Patients with Atrial Fibrillation. Nutrients, 2021, 13, 651.	4.1	7

#	ARTICLE	IF	CITATIONS
37	Prognostic value of inflammatory biomarkers and GRACE score for cardiac death and acute kidney injury after acute coronary syndromes. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 445-452.	1.0	5
38	Impella versus extracorporeal life support in cardiogenic shock: a propensity score adjusted analysis. <i>ESC Heart Failure</i> , 2021, 8, 953-961.	3.1	10
39	Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry. <i>ESC Heart Failure</i> , 2021, 8, 1924-1932.	3.1	8
40	Novel Blood Biomarkers for a Diagnostic Workup of Acute Aortic Dissection. <i>Diagnostics</i> , 2021, 11, 615.	2.6	14
41	Residual inflammatory risk at 12 months after acute coronary syndromes is frequent and associated with combined adverse events. <i>Atherosclerosis</i> , 2021, 320, 31-37.	0.8	7
42	Multi-Omics Approaches to Define Calcific Aortic Valve Disease Pathogenesis. <i>Circulation Research</i> , 2021, 128, 1371-1397.	4.5	39
43	Improving 1-year mortality prediction in ACS patients using machine learning. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 855-865.	1.0	9
44	Long-term dietary supplementation with plant-derived omega-3 fatty acid improves outcome in experimental ischemic stroke. <i>Atherosclerosis</i> , 2021, 325, 89-98.	0.8	8
45	TNF α antagonism rescues the effect of ageing on stroke: Perspectives for targeting inflammation in ageing. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13600.	3.4	17
46	Resilience of the Internal Mammary Artery to Atherogenesis: Shifting From Risk to Resistance to Address Unmet Needs. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2237-2251.	2.4	16
47	ApoA-I mimetics improve aortic stenosis-associated left-ventricular diastolic dysfunction but fail to benefit rabbit models with normal aortic valves. <i>International Journal of Cardiology</i> , 2021, 332, 159-161.	1.7	1
48	Lifelong dietary omega-3 fatty acid suppresses thrombotic potential through gut microbiota alteration in aged mice. <i>IScience</i> , 2021, 24, 102897.	4.1	15
49	Post-COVID-19 Tachycardia Syndrome: A Distinct Phenotype of Post-Acute COVID-19 Syndrome. <i>American Journal of Medicine</i> , 2021, 134, 1451-1456.	1.5	109
50	CCN family member 1 (CCN1) is an early marker of infarct size and left ventricular dysfunction in STEMI patients. <i>Atherosclerosis</i> , 2021, 335, 77-83.	0.8	6
51	Management of refractory angina: an update. <i>European Heart Journal</i> , 2021, 42, 269-283.	2.2	30
52	Inflammation in Metabolic Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 742178.	2.4	42
53	Cysteine-Rich Angiogenic Inducer 61 Improves Prognostic Accuracy of GRACE (Global Registry of Acute) Tj ETQq1 1 0.784314 rgBT Heart Association, 2021, 10, e020488.	3.7	4
54	Association between self-reported motivation to quit smoking with effectiveness of smoking cessation intervention among patients hospitalized for acute coronary syndromes in Switzerland. <i>Preventive Medicine Reports</i> , 2021, 24, 101583.	1.8	0

#	ARTICLE	IF	CITATIONS
55	Clinical and electrocardiographic features of patients with myocardial infarction with non-obstructive coronary artery disease (MINOCA). <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 104-109.	1.5	2
56	The ESC Publications Committee: scope, successes, and challenges 2009–20. <i>Cardiovascular Research</i> , 2021, 117, e13-e16.	3.8	0
57	Cardiovascular Risk Profile, Presentation and Management Outcomes of Patients with Acute Coronary Syndromes after Coronary Artery Bypass Grafting. <i>Current Problems in Cardiology</i> , 2021, , 101078.	2.4	3
58	Macrophage NCOR1 protects from atherosclerosis by repressing a pro-atherogenic PPAR β signature. <i>European Heart Journal</i> , 2020, 41, 995-1005.	2.2	56
59	Prognostic values of fasting hyperglycaemia in non-diabetic patients with acute coronary syndrome: A prospective cohort study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 589-598.	1.0	7
60	Endothelial SIRT6 blunts stroke size and neurological deficit by preserving blood–brain barrier integrity: a translational study. <i>European Heart Journal</i> , 2020, 41, 1575-1587.	2.2	54
61	Clinical Presentation and Laboratory Findings in Men Versus Women with Myocarditis. <i>Journal of Women's Health</i> , 2020, 29, 193-199.	3.3	16
62	Heart non-specific effector CD4+ T cells protect from postinflammatory fibrosis and cardiac dysfunction in experimental autoimmune myocarditis. <i>Basic Research in Cardiology</i> , 2020, 115, 6.	5.9	17
63	Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. <i>European Heart Journal</i> , 2020, 41, 2304-2312.	2.2	54
64	“The lower the better”™ revisited: the new lipid targets in high risk patients. <i>European Heart Journal</i> , 2020, 41, 1-3.	2.2	16
65	Takotsubo syndrome: How the broken heart deals with negative emotions. <i>NeuroImage: Clinical</i> , 2020, 25, 102124.	2.7	4
66	Cardiomyocyte-Specific JunD Overexpression Increases Infarct Size following Ischemia/Reperfusion Cardiac Injury by Downregulating Sirt3. <i>Thrombosis and Haemostasis</i> , 2020, 120, 168-180.	3.4	13
67	Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors. <i>International Journal of Cardiology</i> , 2020, 299, 289-295.	1.7	1
68	The year in cardiology: acute coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 821-832.	2.2	12
69	A revolution in diabetes care: novel drugs and new recommendations. <i>European Heart Journal</i> , 2020, 41, 195-198.	2.2	2
70	Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort. <i>International Journal of Cardiology</i> , 2020, 303, 8-13.	1.7	5
71	Apold1 deficiency associates with increased arterial thrombosis in vivo. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13191.	3.4	8
72	Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 279-287.	2.4	34

#	ARTICLE	IF	CITATIONS
73	Prognosis of Patients with Chronic and Hospital-Acquired Anaemia After Acute Coronary Syndromes. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 618-628.	2.4	8
74	Impact of Coronavirus Disease 2019 Pandemic on the Incidence and Management of Out-of-Hospital Cardiac Arrest in Patients Presenting With Acute Myocardial Infarction in England. <i>Journal of the American Heart Association</i> , 2020, 9, e018379.	3.7	53
75	Repurposing Colchicine to Combat Residual Cardiovascular Risk: The LoDoCo2 Trial. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13424.	3.4	15
76	Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. <i>European Heart Journal</i> , 2020, 41, 3363-3373.	2.2	103
77	Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2020, 41, 2556-2569.	2.2	16
78	Clinical trials in interventional cardiology: a challenging necessity. <i>European Heart Journal</i> , 2020, 41, 2509-2512.	2.2	0
79	The sooner, the better: anti-inflammation in acute myocardial infarction. <i>European Heart Journal</i> , 2020, 41, 4100-4102.	2.2	15
80	Advancing RNA-targeted therapy for personalised prevention of coronary disease: focus on ANGPT3. <i>European Heart Journal</i> , 2020, 41, 3946-3948.	2.2	4
81	Nutrition, obesity, diabetes, and cardiovascular outcomes: a deadly association. <i>European Heart Journal</i> , 2020, 41, 2603-2607.	2.2	4
82	New Mechanisms of Vascular Dysfunction in Cardiometabolic Patients: Focus on Epigenetics. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 363-371.	2.2	12
83	Frontiers in valvular heart disease: outcomes of novel percutaneous procedures. <i>European Heart Journal</i> , 2020, 41, 2717-2720.	2.2	0
84	Inflammation and features of the vulnerable plaque: from mechanisms and imaging to outcomes. <i>European Heart Journal</i> , 2020, 41, 2923-2927.	2.2	9
85	Understanding COVID-19: in the end it is the endothelium what else?. <i>European Heart Journal</i> , 2020, 41, 3023-3027.	2.2	11
86	Clinical benefits and safety of renal denervation in severe arterial hypertension: A long-term follow-up study. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1854-1864.	2.0	7
87	Optimizing management of atrial fibrillation: integrated care, blood pressure control, ablation, and left atrial appendix occlusion. <i>European Heart Journal</i> , 2020, 41, 2821-2825.	2.2	0
88	Hyperglycemia Induces Myocardial Dysfunction via Epigenetic Regulation of JunD. <i>Circulation Research</i> , 2020, 127, 1261-1273.	4.5	38
89	Impact of the COVID-19 Pandemic on Percutaneous Coronary Intervention in England. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009654.	3.9	39
90	Chronic coronary syndromes: perfusion pressure, FFR, and secondary prevention. <i>European Heart Journal</i> , 2020, 41, 1611-1614.	2.2	0

#	ARTICLE	IF	CITATIONS
91	Ageing and longevity genes in cardiovascular diseases. Basic and Clinical Pharmacology and Toxicology, 2020, 127, 120-131.	2.5	21
92	Cardio-oncology and the future of heart failure. European Heart Journal, 2020, 41, 1709-1712.	2.2	1
93	COVID-19: (mis)managing an announced Black Swan. European Heart Journal, 2020, 41, 1779-1782.	2.2	3
94	Glycoprotein Ib clustering in platelets can be inhibited by ω -3-linolenic acid as revealed by cryo-electron tomography. Haematologica, 2020, 105, 1660-1666.	3.5	13
95	Coexistence and outcome of coronary artery disease in Takotsubo syndrome. European Heart Journal, 2020, 41, 3255-3268.	2.2	49
96	Vulnerable plaques and patients: state-of-the-art. European Heart Journal, 2020, 41, 2997-3004.	2.2	98
97	The NO-donor MPC-1011 stimulates angiogenesis and arteriogenesis and improves hindlimb ischemia via a cGMP-dependent pathway involving VEGF and SDF-1 α . Atherosclerosis, 2020, 304, 30-38.	0.8	12
98	Typical and atypical acute coronary syndromes: inflammation, vasoconstriction, and dissection as major mechanisms. European Heart Journal, 2020, 41, 2135-2139.	2.2	1
99	Sudden cardiac death: addressing unresolved issues. European Heart Journal, 2020, 41, 1947-1951.	2.2	1
100	The saga continues: is COVID-19 a cardiopulmonary disease?. European Heart Journal, 2020, 41, 2041-2044.	2.2	1
101	Murine tissue factor disulfide mutation causes a bleeding phenotype with sex specific organ pathology and lethality. Haematologica, 2020, 105, 2484-2495.	3.5	0
102	Towards individualized lifetime risk: combining classical and non-classical factors. European Heart Journal, 2020, 41, 1143-1147.	2.2	2
103	Challenges in atrial fibrillation: detection, alert systems, fibrosis, and infection. European Heart Journal, 2020, 41, 1063-1066.	2.2	2
104	Ejection fraction to classify heart failure: are we using the right thing?. European Heart Journal, 2020, 41, 1219-1222.	2.2	3
105	Optimal Timing of Invasive Coronary Angiography following NSTEMI. Journal of Interventional Cardiology, 2020, 2020, 1-9.	1.2	6
106	How to slice the pie: heart failure subgroups and their clinical meaning. European Heart Journal, 2020, 41, 2339-2343.	2.2	0
107	Vascular medicine: the Cinderella of cardiology back on stage. European Heart Journal, 2020, 41, 2417-2420.	2.2	0
108	Diversity of cardiac patients: An underestimated issue. Revista Portuguesa De Cardiologia (English) Tj ETQq0 0 0 rgBT, /Overlock 10 Tf 50	0,2	0

#	ARTICLE	IF	CITATIONS
109	The next chapter of prevention: from LDL-cholesterol to lipoprotein(a) and triglycerides. <i>European Heart Journal</i> , 2020, 41, 2227-2230.	2.2	2
110	Virome Sequencing in Patients With Myocarditis. <i>Circulation: Heart Failure</i> , 2020, 13, e007103.	3.9	16
111	Understanding cardiovascular disease: macrophage function, LDL-receptor trafficking, and C-type natriuretic peptide. <i>European Heart Journal</i> , 2020, 41, 975-979.	2.2	0
112	Imaging the heart and the brain: from the amygdala to arterial inflammation. <i>European Heart Journal</i> , 2020, 41, 727-730.	2.2	0
113	Valvular heart disease: improved procedural success and prediction of outcomes. <i>European Heart Journal</i> , 2020, 41, 899-902.	2.2	1
114	Frontiers of acute coronary syndromes: primary PCI time window, 15-year outcomes, bleeding and MINOCA. <i>European Heart Journal</i> , 2020, 41, 805-809.	2.2	1
115	Sirt6 deletion in bone marrow-derived cells increases atherosclerosis – Central role of macrophage scavenger receptor 1. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 139, 24-32.	1.9	26
116	Chronic coronary syndromes: expanding the spectrum and natural history of ischaemic heart disease. <i>European Heart Journal</i> , 2020, 41, 333-336.	2.2	1
117	Cardiovascular diseases outside the heart: novel recommendations for pulmonary embolism and peripheral arterial disease. <i>European Heart Journal</i> , 2020, 41, 487-489.	2.2	1
118	Current management of supraventricular tachycardias: the 2019 ESC Guidelines. <i>European Heart Journal</i> , 2020, 41, 607-609.	2.2	0
119	Diversity of cardiac patients: An underestimated issue. <i>Revista Portuguesa De Cardiologia</i> , 2020, 39, 73-75.	0.5	4
120	From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases. <i>European Heart Journal</i> , 2020, 41, 3884-3899.	2.2	58
121	Sex and gender and cardiovascular medicine: impact in diabetes, acute coronary syndromes, and heart failure. <i>European Heart Journal</i> , 2020, 41, 1311-1314.	2.2	6
122	Novel insights into rare cardiomyopathies: arrhythmogenic cardiomyopathy, non-compaction, and transthyretin amyloidosis. <i>European Heart Journal</i> , 2020, 41, 1375-1378.	2.2	0
123	Age-Related Variations in Takotsubo Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1869-1877.	2.8	42
124	Sports cardiology: the benefits of cardiorespiratory fitness in young adults, the elderly, and patients with arrhythmias. <i>European Heart Journal</i> , 2020, 41, 1455-1458.	2.2	1
125	Unanswered questions in hypertension: prematurity and long-term trajectories, masked and white coat hypertension. <i>European Heart Journal</i> , 2020, 41, 1527-1530.	2.2	3
126	Twitter promotion predicts citation rates of cardiovascular articles: a preliminary analysis from the ESC Journals Randomized Study. <i>European Heart Journal</i> , 2020, 41, 3222-3225.	2.2	66

#	ARTICLE	IF	CITATIONS
127	The Hygia trial: Discussions about surprising results. <i>European Heart Journal</i> , 2020, 41, 1600-1600.	2.2	10
128	Myoglobin for Detection of High-Risk Patients with Acute Myocarditis. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 853-863.	2.4	15
129	From TAVI to tricuspid clipping: fine-tuning the management of valvular heart disease. <i>European Heart Journal</i> , 2020, 41, 1863-1866.	2.2	0
130	Classification of Heart Failure: A Farewell to Ejection Fraction?. <i>Anatolian Journal of Cardiology</i> , 2020, 25, 2-6.	0.9	0
131	Misconceptions and Facts About Takotsubo Syndrome. <i>American Journal of Medicine</i> , 2019, 132, 25-31.	1.5	9
132	Deleterious role of endothelial lectin-like oxidized low-density lipoprotein receptor-1 in ischaemia/reperfusion cerebral injury. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 2233-2245.	4.3	15
133	Novel molecular mechanisms of vascular disease: non-coding RNAs, inflammation, and radiation. <i>European Heart Journal</i> , 2019, 40, 2467-2470.	2.2	0
134	Effect of Left Ventricular Conduction Delay on All-Cause and Cardiovascular Mortality (from the Tj ETQq0 0 0 rgBT/Overlock_10 Tf 50 4	1.6	6
135	Refining percutaneous coronary intervention: intracoronary imaging, haemodynamics, P2Y12 antagonists, and public outcomes reporting. <i>European Heart Journal</i> , 2019, 40, 2549-2552.	2.2	0
136	Frontiers of acute coronary and aortic syndromes: outcomes, novel prognostic markers, and cardiogenic shock. <i>European Heart Journal</i> , 2019, 40, 2655-2658.	2.2	0
137	The spectrum of chronic coronary syndromes: genetics, imaging, and management after PCI and CABG. <i>European Heart Journal</i> , 2019, 40, 2381-2384.	2.2	0
138	Frontiers of surgical and catheter-based management of valvular heart disease. <i>European Heart Journal</i> , 2019, 40, 2173-2176.	2.2	0
139	Neurocardiology: the brainâ€heart connection in Takotsubo syndrome. <i>European Heart Journal</i> , 2019, 40, 3062-3063.	2.2	5
140	The spectrum of heart failure: value of left ventricular ejection fraction and its moving trajectories. <i>European Heart Journal</i> , 2019, 40, 2097-2100.	2.2	1
141	Dysfunctional HDL and inflammation: a noxious liaison in adolescents with type 1 diabetes. <i>European Heart Journal</i> , 2019, 40, 3567-3570.	2.2	8
142	The heart and the brain: cardiovascular risk factors, atrial fibrillation, and dementia. <i>European Heart Journal</i> , 2019, 40, 2271-2275.	2.2	4
143	Hypertension: an undertreated known risk factor revisited. <i>European Heart Journal</i> , 2019, 40, 1991-1994.	2.2	2
144	TAVI is on the move! How it compares with surgery and what complications we still have to consider. <i>European Heart Journal</i> , 2019, 40, 3129-3133.	2.2	5

#	ARTICLE	IF	CITATIONS
145	Endocarditis: the Cinderella of Cardiology is back!. European Heart Journal, 2019, 40, 3211-3213.	2.2	1
146	Diabetes and baseline glucose are associated with inflammation, left ventricular function and short- and long-term outcome in acute coronary syndromes: role of the novel biomarker Cyr 61. Cardiovascular Diabetology, 2019, 18, 142.	6.8	21
147	What is the optimal blood pressure? Differences between current guidelines and novel insights into kidney injury. European Heart Journal, 2019, 40, 3443-3446.	2.2	0
148	Chronic coronary syndromes: genetics, shear stress, and biomarkers. European Heart Journal, 2019, 40, 3367-3371.	2.2	3
149	Heart failure with preserved ejection fraction: towards an understanding of an enigma. European Heart Journal, 2019, 40, 3277-3280.	2.2	2
150	Outcomes Associated With Cardiogenic Shock in Takotsubo Syndrome. Circulation, 2019, 139, 413-415.	1.6	75
151	AP-1 (Activated Protein-1) Transcription Factor JunD Regulates Ischemia/Reperfusion Brain Damage via IL-1 β (Interleukin-1 β). Stroke, 2019, 50, 469-477.	2.0	41
152	Prediction of short- and long-term mortality in takotsubo syndrome: the InterTAK Prognostic Score. European Journal of Heart Failure, 2019, 21, 1469-1472.	7.1	20
153	Frontiers in lipid research: lipoprotein(a), apolipoprotein C-III and E, and PCSK9 and inflammation. European Heart Journal, 2019, 40, 2741-2744.	2.2	6
154	Novel insights into body fat distribution and cardiometabolic risk. European Heart Journal, 2019, 40, 2833-2836.	2.2	6
155	Ischaemic and genetic causes of fatal arrhythmias and sudden death. European Heart Journal, 2019, 40, 2927-2930.	2.2	0
156	Channelopathies and sudden cardiac death: genetics and pharmacological triggers. European Heart Journal, 2019, 40, 3067-3070.	2.2	2
157	Risks and management of cardioversion and catheter ablation in atrial fibrillation. European Heart Journal, 2019, 40, 2999-3002.	2.2	0
158	Leaders in Cardiovascular Research: Thomas LÄschler. Cardiovascular Research, 2019, 115, e125-e126.	3.8	0
159	Understanding and preventing atherosclerosis: from bench to bedside. European Heart Journal, 2019, 40, 323-327.	2.2	4
160	Catheter-based management of valvular heart disease: from TAVI to Mitraclip, Cardioband, and tricuspid interventions. European Heart Journal, 2019, 40, 399-403.	2.2	0
161	Refining the management of acute coronary and aortic syndromes. European Heart Journal, 2019, 40, 1893-1897.	2.2	0
162	Cardio-oncology: a new specialty moves to centre stage. European Heart Journal, 2019, 40, 1743-1746.	2.2	3

#	ARTICLE	IF	CITATIONS
163	The spectrum of cardiomyopathies: novel insights into hypertrophic, arrhythmogenic, and amyloid phenotypes. <i>European Heart Journal</i> , 2019, 40, 1655-1659.	2.2	0
164	Arrhythmias and their management in long QT, ARVC, and atrial fibrillation. <i>European Heart Journal</i> , 2019, 40, 1819-1822.	2.2	1
165	Frontiers in today's chronic coronary syndromes: detecting obstructive disease, role of beta-blockers and of anticoagulants. <i>European Heart Journal</i> , 2019, 40, 1387-1390.	2.2	0
166	Right coronary artery motion analysis: a novel method to measure right ventricular systolic function by selective coronary angiography. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1557-1561.	1.5	1
167	Unresolved issues of anticoagulation in atrial fibrillation: age, BMI, reduced dose, and ethnicity. <i>European Heart Journal</i> , 2019, 40, 1477-1481.	2.2	2
168	Coronary artery bypass confers intermediate-term survival benefit over percutaneous coronary intervention with new-generation stents in real-world patients with multivessel coronary artery disease, including left main disease: a retrospective analysis of 6383 patients. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 56, 911-918.	1.4	8
169	Non-steroidal anti-inflammatory drug use in acute myopericarditis: 12-month clinical follow-up. <i>Open Heart</i> , 2019, 6, e000990.	2.3	24
170	Cardiac arrest in takotsubo syndrome: results from the InterTAK Registry. <i>European Heart Journal</i> , 2019, 40, 2142-2151.	2.2	79
171	Trimethyllysine, a trimethylamine N-oxide precursor, provides near- and long-term prognostic value in patients presenting with acute coronary syndromes. <i>European Heart Journal</i> , 2019, 40, 2700-2709.	2.2	79
172	Atrial fibrillation: from biomarkers to CABANA. <i>European Heart Journal</i> , 2019, 40, 1243-1246.	2.2	1
173	TAVI is on the move! Results in low-risk patients, those with mitral disease, and those with cerebral protection. <i>European Heart Journal</i> , 2019, 40, 1309-1312.	2.2	0
174	The growing spectrum of cardiomyopathies: risk assessment and management. <i>European Heart Journal</i> , 2019, 40, 945-948.	2.2	0
175	Altered limbic and autonomic processing supports brain-heart axis in Takotsubo syndrome. <i>European Heart Journal</i> , 2019, 40, 1183-1187.	2.2	145
176	Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention. <i>PLoS ONE</i> , 2019, 14, e0211464.	2.5	6
177	In search of optimal blood pressure. <i>European Heart Journal</i> , 2019, 40, 707-710.	2.2	0
178	Pheochromocytoma triggers takotsubo syndrome. <i>European Heart Journal</i> , 2019, 40, 1990-1990.	2.2	5
179	Inflammation during acute coronary syndromes – Risk of cardiovascular events and bleeding. <i>International Journal of Cardiology</i> , 2019, 287, 13-18.	1.7	22
180	The year in arrhythmias: real-world data on risk factors, ablation, and genetics. <i>European Heart Journal</i> , 2019, 40, 791-794.	2.2	0

#	ARTICLE	IF	CITATIONS
181	Five-year clinical outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial: randomized comparison of biodegradable polymer-based biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2019, 40, 1909-1919.	2.2	32
182	Peripheral and pulmonary artery disease: an update on under-recognized cardiovascular issues. <i>European Heart Journal</i> , 2019, 40, 861-864.	2.2	0
183	The expanding spectrum of acute coronary syndromes: from STEMI to coronary dissection and Takotsubo syndrome. <i>European Heart Journal</i> , 2019, 40, 1169-1172.	2.2	1
184	Novel findings in neutrophil biology and their impact on cardiovascular disease. <i>Cardiovascular Research</i> , 2019, 115, 1266-1285.	3.8	118
185	Grown-up congenital heart disease: building evidence where it is badly needed. <i>European Heart Journal</i> , 2019, 40, 1027-1030.	2.2	0
186	Mouse Models for Atherosclerosis Researchâ€”Which Is My Line?. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 46.	2.4	118
187	Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13117.	3.4	24
188	Forgotten cardiovascular risk factors: pregnancy complications and preterm birth, bullying, periodontal disease, and hypoxic burden. <i>European Heart Journal</i> , 2019, 40, 1093-1096.	2.2	1
189	What happened this year in heart failure? Moving towards a more individualized approach. <i>European Heart Journal</i> , 2019, 40, 637-639.	2.2	0
190	Imaging the left ventricle: diagnostic and prognostic implications in cardiomyopathies. <i>European Heart Journal</i> , 2019, 40, 495-498.	2.2	1
191	Noise, pollution, food, or medication: what really matters in primary prevention?. <i>European Heart Journal</i> , 2019, 40, 563-566.	2.2	0
192	Impact of Final Kissing Balloon and of Imaging on Patients Treated on Unprotected Left Main Coronary Artery With Thin-Strut Stents (From the RAIN-CARDIOGROUP VII Study). <i>American Journal of Cardiology</i> , 2019, 123, 1610-1619.	1.6	20
193	Inclusion of multiple inappropriate studies in a meta-analysis of randomized controlled trials of atorvastatin loading prior to percutaneous coronary intervention for acute coronary syndrome: editorâ€™s response. <i>European Heart Journal</i> , 2019, 40, 943-943.	2.2	2
194	Novel cardiovascular risk factors: air pollution, air temperature, pain, and sleep duration. <i>European Heart Journal</i> , 2019, 40, 1577-1580.	2.2	7
195	Preventive cardiology in adolescents and the elderly: LDL, HDL, and inflammation. <i>European Heart Journal</i> , 2019, 40, 3503-3506.	2.2	0
196	HFpEF: an enigma being slowly but surely unravelled. <i>European Heart Journal</i> , 2019, 40, 3659-3662.	2.2	0
197	Cardio-oncology: low-grade inflammation as a common pathway of cancer and cardiovascular disease. <i>European Heart Journal</i> , 2019, 40, 3871-3874.	2.2	9
198	Interleukin-1 β Mediates Arterial Thrombus Formation via NET-Associated Tissue Factor. <i>Journal of Clinical Medicine</i> , 2019, 8, 2072.	2.4	70

#	ARTICLE	IF	CITATIONS
199	Optimizing heart failure management: anticoagulation, diuretic withdrawal, iron substitution, and novel inotropes. <i>European Heart Journal</i> , 2019, 40, 3579-3582.	2.2	2
200	Cardiovascular issues in women: expanding diversity in medicine. <i>European Heart Journal</i> , 2019, 40, 3807-3811.	2.2	0
201	Between Scylla and Charybdis: combining anticoagulants with platelet inhibitors and outcome. <i>European Heart Journal</i> , 2019, 40, 3737-3740.	2.2	1
202	Changes in Coronary Plaque Composition in Patients With Acute Myocardial Infarction Treated With High-Intensity Statin Therapy (IBIS-4). <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1518-1528.	5.3	61
203	Sports cardiology: towards the sweet spot in competitive and leisure exercise. <i>European Heart Journal</i> , 2019, 40, 1-4.	2.2	27
204	Myocardial revascularization: guideline-based therapy today. <i>European Heart Journal</i> , 2019, 40, 75-78.	2.2	6
205	Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy. <i>European Heart Journal</i> , 2019, 40, 997-1008.	2.2	69
206	Myocardial injury and myocardial infarction: the various ways of losing myocytes and their prognostic impact. <i>European Heart Journal</i> , 2019, 40, 223-225.	2.2	0
207	Pre-existing treatment with aspirin or statins influences clinical presentation, infarct size and inflammation in patients with de novo acute coronary syndromes. <i>International Journal of Cardiology</i> , 2019, 275, 171-178.	1.7	16
208	Gut microbiota-dependent trimethylamine-N-oxide (TMAO) shows a U-shaped association with mortality but not with recurrent venous thromboembolism. <i>Thrombosis Research</i> , 2019, 174, 40-47.	1.7	29
209	Gender and age differences in outcomes of patients with acute coronary syndromes referred for coronary angiography. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 16-24.	1.7	3
210	Increased Expression of miR-483-3p Impairs the Vascular Response to Injury in Type 2 Diabetes. <i>Diabetes</i> , 2019, 68, 349-360.	0.6	42
211	Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity. <i>European Heart Journal</i> , 2019, 40, 383-391.	2.2	45
212	Systematic use of cardiac magnetic resonance imaging in MINOCA led to a five-fold increase in the detection rate of myocarditis: a retrospective study. <i>Swiss Medical Weekly</i> , 2019, 149, w20098.	1.6	14
213	Gender Differences in Types, Frequency, Clinical Manifestations and Atherosclerotic Burden of Coronary Artery Anomalies. <i>Reviews on Recent Clinical Trials</i> , 2019, 14, 41-46.	0.8	0
214	The London PCHF: A new Postgraduate Course on Heart Failure. <i>Cardiology Journal</i> , 2019, 26, 109-113.	1.2	7
215	Association between income and control of cardiovascular risk factors after acute coronary syndromes: an observational study. <i>Swiss Medical Weekly</i> , 2019, 149, w20049.	1.6	1
216	The future of scientific publishing. <i>EuroIntervention</i> , 2019, 15, 140-146.	3.2	1

#	ARTICLE	IF	CITATIONS
217	Novel insights in HFpEF, cardiomyopathies, and myocarditis. <i>European Heart Journal</i> , 2018, 39, 819-822.	2.2	1
218	Cutting edge research on transcatheter aortic valve implantation: moving indications, complications, and current outcomes. <i>European Heart Journal</i> , 2018, 39, 633-636.	2.2	1
219	Peripheral arterial disease guidelines: the Cinderella of cardiovascular medicine gets the attention it deserves. <i>European Heart Journal</i> , 2018, 39, 717-719.	2.2	0
220	Atrial fibrillation and arrhythmias: novel risk assessment, proper anticoagulation, and ablation. <i>European Heart Journal</i> , 2018, 39, 1317-1321.	2.2	1
221	Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST-Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	11
222	Sirtuin 5 as a novel target to blunt blood-brain barrier damage induced by cerebral ischemia/reperfusion injury. <i>International Journal of Cardiology</i> , 2018, 260, 148-155.	1.7	64
223	Lipids and lipid lowering: current management with statins and PCSK9 inhibitors. <i>European Heart Journal</i> , 2018, 39, 1117-1120.	2.2	0
224	Renal nerve ablation reduces blood pressure in resistant hypertension: Long-term clinical outcomes in a single-center experience. <i>Journal of Clinical Hypertension</i> , 2018, 20, 627-633.	2.0	8
225	Mitral valve disease: news from the frontier in valvular heart disease. <i>European Heart Journal</i> , 2018, 39, 1211-1214.	2.2	0
226	Frontiers in cardiovascular prevention. <i>European Heart Journal</i> , 2018, 39, 329-332.	2.2	2
227	Non-invasive screening for coronary artery disease in asymptomatic diabetic patients: a systematic review and meta-analysis of randomised controlled trials. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 838-846.	1.2	36
228	Epidemiology of cardiovascular disease: the new ESC Atlas and beyond. <i>European Heart Journal</i> , 2018, 39, 489-492.	2.2	12
229	Loss of Sirt3 accelerates arterial thrombosis by increasing formation of neutrophil extracellular traps and plasma tissue factor activity. <i>Cardiovascular Research</i> , 2018, 114, 1178-1188.	3.8	44
230	Frontiers in cardiac imaging: diagnostic and prognostic validity and safety. <i>European Heart Journal</i> , 2018, 39, 259-261.	2.2	1
231	Dual antiplatelet therapy: how, how long, and in which patients?. <i>European Heart Journal</i> , 2018, 39, 181-183.	2.2	2
232	Progress in the management of arrhythmias: risk scores, ablation, and anticoagulation. <i>European Heart Journal</i> , 2018, 39, 421-424.	2.2	1
233	Retinal microvascular dysfunction in heart failure. <i>European Heart Journal</i> , 2018, 39, 47-56.	2.2	91
234	ST-segment elevation myocardial infarction: the new ESC Guidelines. <i>European Heart Journal</i> , 2018, 39, 75-78.	2.2	4

#	ARTICLE	IF	CITATIONS
235	Heart failure subgroups: HFrEF, HFmrEF, and HFpEF with or without mitral regurgitation. <i>European Heart Journal</i> , 2018, 39, 1-4.	2.2	28
236	The year in cardiology 2017: acute coronary syndromes. <i>European Heart Journal</i> , 2018, 39, 1054-1064.	2.2	9
237	The circadian clock in cardiovascular regulation and disease: Lessons from the Nobel Prize in Physiology or Medicine 2017. <i>European Heart Journal</i> , 2018, 39, 2326-2329.	2.2	53
238	Refining cardiovascular risk: anthropometric measures, potassium, high altitude exposure, and cancer therapy. <i>European Heart Journal</i> , 2018, 39, 1499-1502.	2.2	3
239	Acute coronary syndromes: the tipping point of coronary artery disease. <i>European Heart Journal</i> , 2018, 39, 1041-1043.	2.2	1
240	Outcome of congenital heart disease with modern cardiac care. <i>European Heart Journal</i> , 2018, 39, 969-971.	2.2	3
241	New prospects for PCSK9 inhibition?. <i>European Heart Journal</i> , 2018, 39, 2600-2601.	2.2	13
242	Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2018, 20, 125-133.	7.1	317
243	Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 129-138.	1.0	70
244	Thrombus aspiration in acute coronary syndromes: prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 522-531.	1.0	7
245	2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. <i>European Heart Journal</i> , 2018, 39, 1131-1143.	2.2	171
246	Epigenetics and cardiovascular regenerative medicine in the elderly. <i>International Journal of Cardiology</i> , 2018, 250, 207-214.	1.7	41
247	Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. <i>European Heart Journal</i> , 2018, 39, 2540-2545.	2.2	113
248	Untargeted metabolomics identifies trimethyllysine, a TMAO-producing nutrient precursor, as a predictor of incident cardiovascular disease risk. <i>JCI Insight</i> , 2018, 3, .	5.0	122
249	Acute coronary syndromes: the impressive impact of guideline-based management in NSTEMI. <i>European Heart Journal</i> , 2018, 39, 3753-3756.	2.2	1
250	Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention?. <i>European Heart Journal</i> , 2018, 39, 4109-4111.	2.2	44
251	Dangerous encounters: triggers of fatal ventricular arrhythmias and safety of interventional treatment strategies. <i>European Heart Journal</i> , 2018, 39, 3909-3912.	2.2	6
252	The Impact Factor: sparkling or still?. <i>European Heart Journal</i> , 2018, 39, 3844-3846.	2.2	2

#	ARTICLE	IF	CITATIONS
253	Personalized approaches to heart failure: age, acute presentation, and comorbidities. <i>European Heart Journal</i> , 2018, 39, 4223-4226.	2.2	3
254	Assessing myocardial ischaemia in epicardial coronaries and the microcirculation. <i>European Heart Journal</i> , 2018, 39, 4047-4050.	2.2	1
255	Arterial and pulmonary hypertension: risk assessment and current pharmacological and interventional management. <i>European Heart Journal</i> , 2018, 39, 4127-4131.	2.2	5
256	Atrial fibrillation: overall cardiovascular risk beyond stroke and current management. <i>European Heart Journal</i> , 2018, 39, 3983-3986.	2.2	0
257	Inflammation: the new cardiovascular risk factor. <i>European Heart Journal</i> , 2018, 39, 3483-3487.	2.2	17
258	Acute and chronic coronary syndromes: coronary dissection, intraplaque haemorrhage, and late lumen loss. <i>European Heart Journal</i> , 2018, 39, 3339-3342.	2.2	2
259	Preventing coronary artery disease, stroke, and aortic valve disease. <i>European Heart Journal</i> , 2018, 39, 3623-3626.	2.2	0
260	Prognostic Value of SYNTAX Score II in Patients with Acute Coronary Syndromes Referred for Invasive Management: A Subanalysis from the SPUM and COMFORTABLE AMI Cohorts. <i>Cardiology Research and Practice</i> , 2018, 2018, 1-11.	1.1	9
261	Valvular heart disease: tricuspid regurgitation is the new frontier. <i>European Heart Journal</i> , 2018, 39, 3555-3557.	2.2	6
262	Frontiers in cardiovascular computed tomography: FFRCT, CT/PET, and radiation exposure. <i>European Heart Journal</i> , 2018, 39, 3675-3678.	2.2	0
263	Assessing coronary plaques: non-invasive and intracoronary imaging and haemodynamic measurements. <i>European Heart Journal</i> , 2018, 39, 3265-3268.	2.2	0
264	Congenital heart and aortic disease: novel genetic causes, biomarkers, and effect of pregnancy. <i>European Heart Journal</i> , 2018, 39, 3149-3151.	2.2	1
265	Hypertension is on the move! The new ESC Guidelines and more. <i>European Heart Journal</i> , 2018, 39, 3003-3006.	2.2	0
266	Post-ischaemic administration of the murine Canakinumab-surrogate antibody improves outcome in experimental stroke. <i>European Heart Journal</i> , 2018, 39, 3511-3517.	2.2	48
267	Mechanisms and outcomes of heart failure: from HFpEF, HFmrEF, and HFREF to transplantation. <i>European Heart Journal</i> , 2018, 39, 1749-1753.	2.2	5
268	Ischemic stroke across sexes: What is the status quo?. <i>Frontiers in Neuroendocrinology</i> , 2018, 50, 3-17.	5.2	23
269	The effect of oxygen in Sirt3-mediated myocardial protection: a proof-of-concept study in cultured cardiomyoblasts. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 102-112.	2.1	0
270	International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. <i>European Heart Journal</i> , 2018, 39, 2032-2046.	2.2	972

#	ARTICLE	IF	CITATIONS
271	International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. <i>European Heart Journal</i> , 2018, 39, 2047-2062.	2.2	521
272	Anticoagulation in clinically difficult situations: insights into safe and effective management. <i>European Heart Journal</i> , 2018, 39, 1657-1660.	2.2	0
273	Hybrid SPECT Perfusion Imaging and Coronary CT Angiography: Long-term Prognostic Value for Cardiovascular Outcomes. <i>Radiology</i> , 2018, 288, 694-702.	7.3	35
274	Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66Shc. <i>International Journal of Cardiology</i> , 2018, 268, 179-186.	1.7	47
275	Prevention: From Lifestyle Changes to Medication. <i>European Heart Journal</i> , 2018, 39, 2333-2336.	2.2	0
276	Back to square one: what is a normal blood pressure and for whom?. <i>European Heart Journal</i> , 2018, 39, 2221-2225.	2.2	2
277	Improving outcomes after acute coronary events: what works and what doesn't. <i>European Heart Journal</i> , 2018, 39, 2691-2694.	2.2	2
278	Performance of modern stents in stable and acute coronary disease. <i>European Heart Journal</i> , 2018, 39, 2435-2438.	2.2	0
279	"The lower the better" revisited: low-density lipoprotein and lipoprotein(a). <i>European Heart Journal</i> , 2018, 39, 2509-2512.	2.2	3
280	TAVI: from an experimental procedure to standard of care. <i>European Heart Journal</i> , 2018, 39, 2605-2608.	2.2	4
281	Prognostic value of pulse pressure after an acute coronary syndrome. <i>Atherosclerosis</i> , 2018, 277, 219-226.	0.8	15
282	Coronary and structural interventions: novel evidence for decision making. <i>European Heart Journal</i> , 2018, 39, 1577-1580.	2.2	1
283	Causes and prevention of sudden cardiac death: ECG, electroanatomical mapping, fibrosis, and channelopathies. <i>European Heart Journal</i> , 2018, 39, 2841-2844.	2.2	0
284	Heart failure with preserved ejection fraction: unravelling an enigma. <i>European Heart Journal</i> , 2018, 39, 2763-2766.	2.2	4
285	Long-Term Prognosis of Patients With Takotsubo Syndrome. <i>Journal of the American College of Cardiology</i> , 2018, 72, 874-882.	2.8	224
286	The 2018 ESC-ESH guidelines for the management of arterial hypertension leave clinicians facing a dilemma in half of the patients. <i>European Heart Journal</i> , 2018, 39, 4040-4041.	2.2	14
287	CANTOS: a seductive song with several verses. <i>European Heart Journal</i> , 2018, 39, 3508-3510.	2.2	3
288	The <i>European Heart Journal</i> : Again, Number One in Cardiovascular Medicine!. <i>European Heart Journal</i> , 2018, 39, 3343-3345.	2.2	0

#	ARTICLE	IF	CITATIONS
289	Atrial fibrillation and stroke: anticoagulation in trials and real-world settings. <i>European Heart Journal</i> , 2018, 39, 2915-2918.	2.2	0
290	Effect of Aortic Valve Calcium Quantity on Outcome After Balloon Aortic Valvuloplasty for Severe Aortic Stenosis. <i>American Journal of Cardiology</i> , 2018, 122, 1036-1041.	1.6	0
291	Approximation of the Incidence of Myocarditis by Systematic Screening With Cardiac Magnetic Resonance Imaging. <i>JACC: Heart Failure</i> , 2018, 6, 573-579.	4.1	33
292	Takotsubo syndrome: the Cinderella compared with common acute coronary syndromes. <i>European Heart Journal</i> , 2018, 39, 2017-2020.	2.2	1
293	Revisiting angina pectoris with and without obstructive coronary artery disease. <i>European Heart Journal</i> , 2018, 39, 2119-2122.	2.2	3
294	What is a normal blood pressure?. <i>European Heart Journal</i> , 2018, 39, 2233-2240.	2.2	14
295	Predictive value of the age, creatinine, and ejection fraction (ACEF) score in patients with acute coronary syndromes. <i>International Journal of Cardiology</i> , 2018, 270, 7-13.	1.7	33
296	ESC CardioMed. <i>Cardiology Journal</i> , 2018, 25, 565-568.	1.2	3
297	Impact of gender on outcomes after transcatheter aortic valve implantation. <i>Journal of Geriatric Cardiology</i> , 2018, 15, 394-400.	0.2	6
298	Short-Term Outcome After Left Main Interventions in Patients Presenting With Acute Coronary Syndrome. <i>Journal of Invasive Cardiology</i> , 2018, 30, 98-104.	0.4	3
299	Heart failure: drugs, surgery, and assist devices. <i>European Heart Journal</i> , 2018, 39, 3401-3404.	2.2	0
300	Profiling and validation of circulating microRNAs for cardiovascular events in patients presenting with ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2017, 38, ehw563.	2.2	77
301	Transforming growth factor- β -dependent Wnt secretion controls myofibroblast formation and myocardial fibrosis progression in experimental autoimmune myocarditis. <i>European Heart Journal</i> , 2017, 38, ehw116.	2.2	134
302	European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. <i>European Heart Journal</i> , 2017, 38, ehw480.	2.2	137
303	Interventional therapy for hypertension: Back on track again?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 18-25.	6.1	0
304	Optical coherence tomography evaluation of intermediate-term healing of different stent types: systemic review and meta-analysis. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 159-166.	1.2	63
305	Increased Proangiogenic Activity of Mobilized CD34 ⁺ Progenitor Cells of Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 341-349.	2.4	40
306	Ticagrelor, but not clopidogrel active metabolite, displays antithrombotic properties in the left atrial endocardium. <i>European Heart Journal</i> , 2017, 38, ehw578.	2.2	9

#	ARTICLE	IF	CITATIONS
307	Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. <i>European Heart Journal</i> , 2017, 38, ehw582.	2.2	317
308	The REMEDEE-OCT Study. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 489-499.	2.9	35
309	Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase. <i>Atherosclerosis</i> , 2017, 257, 186-194.	0.8	17
310	The Aging Cardiovascular System. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1952-1967.	2.8	400
311	Relationship Between Peak Troponin Values and Long-Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	8
312	Reduced nitric oxide bioavailability mediates cerebroarterial dysfunction independent of cerebral amyloid angiopathy in a mouse model of Alzheimer's disease. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017, 312, H232-H238.	3.2	27
313	Accuracy of smartphone apps for heart rate measurement. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1287-1293.	1.8	105
314	Endothelial LOX-1 activation differentially regulates arterial thrombus formation depending on oxLDL levels: role of the Oct-1/SIRT1 and ERK1/2 pathways. <i>Cardiovascular Research</i> , 2017, 113, 498-507.	3.8	27
315	Turbulent Kinetic Energy Assessed by Multipoint 4-Dimensional Flow Magnetic Resonance Imaging Provides Additional Information Relative to Echocardiography for the Determination of Aortic Stenosis Severity. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	2.6	60
316	Impact of Glycemic Variability on Chromatin Remodeling, Oxidative Stress, and Endothelial Dysfunction in Patients With Type 2 Diabetes and With Target HbA1c Levels. <i>Diabetes</i> , 2017, 66, 2472-2482.	0.6	139
317	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. <i>American Journal of Medicine</i> , 2017, 130, S18-S29.	1.5	67
318	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. <i>American Journal of Cardiology</i> , 2017, 120, S17-S27.	1.6	66
319	Burden and impact of congenital syndromes and comorbidities among adults with congenital heart disease. <i>International Journal of Cardiology</i> , 2017, 240, 159-164.	1.7	16
320	Prognostic value of mean pulmonary artery pressure in the stable phase after heart transplantation. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 775-780.	1.4	5
321	Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 198-213.	3.0	18
322	Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease. <i>European Heart Journal</i> , 2017, 38, 1597-1607.	2.2	77
323	Prognostic value of long-term blood pressure changes in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 837-842.	7.1	32
324	The year in cardiology 2016: acute coronary syndromes. <i>European Heart Journal</i> , 2017, 38, ehw620.	2.2	4

#	ARTICLE	IF	CITATIONS
325	A novel clinical score (<scp>InterTAK</scp> Diagnostic Score) to differentiate takotsubo syndrome from acute coronary syndrome: results from the International Takotsubo Registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1036-1042.	7.1	142
326	Percutaneous Coronary Intervention of Chronic Total Occlusions in Patients With Low Left Ventricular Ejection Fraction. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2158-2170.	2.9	79
327	Special issues in heart failure: pulmonary hypertension, deranged potassium levels, and haemodynamic profiles. <i>European Heart Journal</i> , 2017, 38, 2857-2859.	2.2	0
328	From Eisenhowerâ€™s heart attack to modern management: a true success story!. <i>European Heart Journal</i> , 2017, 38, 3066-3069.	2.2	37
329	Stem cell therapy: from translational hurdles to new frontiers. <i>European Heart Journal</i> , 2017, 38, 2915-2918.	2.2	0
330	Sudden cardiac death: new aspects of a continuing clinical challenge. <i>European Heart Journal</i> , 2017, 38, 2973-2976.	2.2	0
331	Impact of stroke volume assessment by integrating multi-detector computed tomography and Doppler data on the classification of aortic stenosis. <i>International Journal of Cardiology</i> , 2017, 246, 80-86.	1.7	13
332	Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance. <i>Haematologica</i> , 2017, 102, 1650-1660.	3.5	49
333	Multi-centre study of whole-heart dynamic 3D cardiac magnetic resonance perfusion imaging for the detection of coronary artery disease defined by fractional flow reserve: gender based analysis of diagnostic performance. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 1099-1106.	1.2	9
334	Catecholamine-Dependent Î²-Adrenergic Signaling in a Pluripotent Stem Cell Model of Takotsubo Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2017, 70, 975-991.	2.8	124
335	Rehospitalizations Following Primary Percutaneous Coronary Intervention in Patients With STâ€Elevation Myocardial Infarction: Results From a Multiâ€Center Randomized Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	10
336	Long-term incidence of inappropriate shocks in patients with implantable cardioverter defibrillators in clinical practiceâ€”an underestimated complication?. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 50, 219-226.	1.3	20
337	Inhibition of Vascular câ€Jun Nâ€Terminal Kinase 2 Improves Obesityâ€Induced Endothelial Dysfunction After Rouxâ€Y Gastric Bypass. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	4
338	Cardiac Magnetic Resonance Imaging in Myocarditis Reveals Persistent Disease Activity Despite Normalization of Cardiac Enzymes and Inflammatory Parameters at 3-Month Follow-Up. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	55
339	Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	29
340	Intracardiac versus transesophageal echocardiography for left atrial appendage occlusion with watchman. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 331-338.	1.7	53
341	Optimizing percutaneous coronary interventions: Heart Team, SYNTAX II Score, physiology and imaging guidance, modern stents, and guideline-based medication. <i>European Heart Journal</i> , 2017, 38, 3109-3113.	2.2	5
342	Frontiers of Prevention: Pollution, Infection, Cognitive Function and Frailty. <i>European Heart Journal</i> , 2017, 38, 3179-3182.	2.2	2

#	ARTICLE	IF	CITATIONS
343	Frontiers of lipid research: cholesterol variability, HDL biogenesis, genetics of myalgia, and lipoprotein(a). <i>European Heart Journal</i> , 2017, 38, 3541-3544.	2.2	1
344	Acute coronary syndromes: early diagnosis, management, and risk prediction. <i>European Heart Journal</i> , 2017, 38, 3037-3040.	2.2	1
345	Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes. <i>European Heart Journal</i> , 2017, 38, 3493-3502.	2.2	46
346	In response to the comment by Hechler <i>et al</i> : Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.. <i>Haematologica</i> , 2017, 102, e504-e505.	3.5	2
347	Managing aortic stenosis with TAVI or surgery: risk assesement and long-term outcome. <i>European Heart Journal</i> , 2017, 38, 3327-3329.	2.2	1
348	Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i> <i>European Heart Journal</i> , 2017, 38, 3282-3292.	2.2	86
349	Controversies in hypertension management: target blood pressure, renal nerve ablation, ARNIs, and NSAIDs medication. <i>European Heart Journal</i> , 2017, 38, 3245-3248.	2.2	0
350	From "essential" hypertension to intensive blood pressure lowering: the pros and cons of lower target values. <i>European Heart Journal</i> , 2017, 38, 3258-3271.	2.2	13
351	Global position paper on cardiovascular regenerative medicine. <i>European Heart Journal</i> , 2017, 38, 2532-2546.	2.2	133
352	Percutaneous Intervention of a Single Coronary Artery in the Setting of Acute Coronary Syndrome. <i>Cardiology Research</i> , 2017, 8, 349-353.	1.1	1
353	Tissue Factor Expression Does Not Predict Mortality in Breast Cancer Patients. <i>Anticancer Research</i> , 2017, 37, 3259-3264.	1.1	4
354	High blood pressure: new frontiers of an old risk factor. <i>European Heart Journal</i> , 2017, 38, 2791-2794.	2.2	0
355	ECG Criteria to Differentiate Between Takotsubo (Stress) Cardiomyopathy and Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	111
356	Eminence, common sense, and evidence: a comment to the Andreas GrÄntzig lecture 2015. <i>European Heart Journal</i> , 2016, 37, 2020-2022.	2.2	3
357	Meta-Analysis of the Duration of Dual Antiplatelet Therapy in Patients Treated With Second-Generation Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2016, 117, 1714-1723.	1.6	57
358	Relation of Longitudinal Changes in Quality of Life Assessments to Changes in Functional Capacity in Patients With Heart Failure With and Without Anemia. <i>American Journal of Cardiology</i> , 2016, 117, 1482-1487.	1.6	12
359	Differences in the Clinical Profile and Outcomes of Typical and Atypical Takotsubo Syndrome. <i>JAMA Cardiology</i> , 2016, 1, 335.	6.1	189
360	Mild endothelial dysfunction in Sirt3 knockout mice fed a high-cholesterol diet: protective role of a novel C/EBP- β -dependent feedback regulation of SOD2. <i>Basic Research in Cardiology</i> , 2016, 111, 33.	5.9	28

#	ARTICLE	IF	CITATIONS
361	Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. <i>European Heart Journal</i> , 2016, 37, 1967-1976.	2.2	433
362	Carbamylated Low-Density Lipoproteins Induce a Prothrombotic State Via LOX-1. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1664-1676.	2.8	52
363	Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the <scp>TRILogy ACS</scp> Trial. <i>Clinical Cardiology</i> , 2016, 39, 497-506.	1.8	5
364	Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Clinical Cardiology</i> , 2016, 39, 285-290.	1.8	8
365	Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial. <i>European Heart Journal</i> , 2016, 37, 3386-3395.	2.2	80
366	Safety and efficacy profile of <i>bioresorbable</i>-polylactide-polymer-biolimus-eluting stents versus <i>durable</i>-polymer-everolimus and zotarolimus-eluting stents in patients with acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, E173-E182.	1.7	5
367	Pre-hospital alarm activation for STEMI patients undergoing primary percutaneous coronary intervention in the era of transradial procedures. <i>European Journal of Internal Medicine</i> , 2016, 35, 83-88.	2.2	1
368	“One-Stop Shop”. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1487-1495.	2.9	29
369	Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. <i>New England Journal of Medicine</i> , 2016, 375, 2519-2529.	27.0	607
370	Uptake and efficacy of a systematic intensive smoking cessation intervention using motivational interviewing for smokers hospitalised for an acute coronary syndrome: a multicentre before-after study with parallel group comparisons. <i>BMJ Open</i> , 2016, 6, e011520.	1.9	18
371	Effect of Bone Marrow-Derived Mononuclear Cell Treatment, Early or Late After Acute Myocardial Infarction. <i>Circulation Research</i> , 2016, 119, 481-490.	4.5	75
372	The Electrocardiogram After Transcatheter Aortic Valve Replacement Determines the Risk for Post-Procedural High-Degree AV Block and the Need for Telemetry Monitoring. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1269-1276.	2.9	114
373	Decreased phosphatidylcholine plasmalogens – A putative novel lipid signature in patients with stable coronary artery disease and acute myocardial infarction. <i>Atherosclerosis</i> , 2016, 246, 130-140.	0.8	47
374	Myocardial expression profiles of candidate molecules in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia compared to those with dilated cardiomyopathy and healthy controls. <i>Heart Rhythm</i> , 2016, 13, 731-741.	0.7	32
375	Prognostic value of PCSK9 levels in patients with acute coronary syndromes. <i>European Heart Journal</i> , 2016, 37, 546-553.	2.2	120
376	Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy. <i>Atherosclerosis</i> , 2016, 247, 154-160.	0.8	22
377	Pin1 inhibitor Juglone prevents diabetic vascular dysfunction. <i>International Journal of Cardiology</i> , 2016, 203, 702-707.	1.7	39
378	Reprogramming ageing and longevity genes restores paracrine angiogenic properties of early outgrowth cells. <i>European Heart Journal</i> , 2016, 37, 1733-1737.	2.2	27

#	ARTICLE	IF	CITATIONS
379	Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 152-167.	3.0	50
380	P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 229-243.	3.0	46
381	MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart. <i>European Heart Journal</i> , 2016, 37, 572-576.	2.2	136
382	Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary artery disease: a meta-analysis. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 1128-1137.	1.2	107
383	Association of left bundle branch block with obstructive coronary artery disease on coronary CT angiography: a case-control study. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 765-771.	1.2	6
384	Elevated high-sensitivity troponin T levels are associated with adverse cardiac remodelling and myocardial fibrosis in hypertrophic cardiomyopathy. <i>Swiss Medical Weekly</i> , 2016, 146, w14285.	1.6	15
385	A Model of Platelets in the Aging Organism Reveals Increased Numbers Due to Reduced Clearance and Enhanced Activatability of Gp2b/3a and P-Selectin, Resulting in a Larger Stroke Burden. <i>Blood</i> , 2016, 128, 3724-3724.	1.4	0
386	EJH – Cardiovascular Pharmacotherapy: a warm welcome to the new member of the ESC journal family. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 2-6.	3.0	1
387	Calcification Characteristics of Low-Flow Low-Gradient Severe Aortic Stenosis in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Cardiology Research and Practice</i> , 2015, 2015, 1-8.	1.1	2
388	The Sirt1 activator SRT3025 provides atheroprotection in ApoE ^{-/-} mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. <i>European Heart Journal</i> , 2015, 36, 51-59.	2.2	117
389	Inpatient versus outpatient onsets of acute myocardial infarction. <i>European Journal of Internal Medicine</i> , 2015, 26, 414-419.	2.2	18
390	Incidence and Prognosis of Ventricular Arrhythmias in Patients with Congenital Left Ventricular Aneurysms or Diverticula. <i>American Journal of Medicine</i> , 2015, 128, 653.e1-653.e6.	1.5	13
391	Low statin use in adults hospitalized with acute coronary syndrome. <i>Preventive Medicine</i> , 2015, 77, 131-136.	3.4	18
392	Filling a gap in the ESC Journal Family: a warm welcome to the EJH – Quality of Care and Clinical Outcomes. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2015, 1, 3-6.	4.0	0
393	Rheumatoid arthritis and coronary atherosclerosis: two cousins engaging in a dangerous liaison. <i>European Heart Journal</i> , 2015, 36, 3423-3425.	2.2	22
394	Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations: Table 1. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 232-244.	3.0	13
395	Acute rupture of a thin cap fibroatheroma: value of multimodality imaging. <i>European Heart Journal</i> , 2015, 36, 1001-1001.	2.2	1
396	Rapid and Body Weight-Independent Improvement of Endothelial and High-Density Lipoprotein Function After Roux-en-Y Gastric Bypass. <i>Circulation</i> , 2015, 131, 871-881.	1.6	103

#	ARTICLE	IF	CITATIONS
397	Left-sided haemothorax after iatrogenic coronary perforation in a patient with prior bypass surgery. <i>European Heart Journal</i> , 2015, 36, 128-128.	2.2	6
398	Cardiovascular magnetic resonance for the assessment of coronary artery disease. <i>International Journal of Cardiology</i> , 2015, 193, 84-92.	1.7	13
399	Circulating FABP4 Is a Prognostic Biomarker in Patients With Acute Coronary Syndrome but Not in Asymptomatic Individuals. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1872-1879.	2.4	36
400	Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. <i>European Heart Journal</i> , 2015, 36, 2438-2445.	2.2	129
401	The perils of surrogate endpoints. <i>European Heart Journal</i> , 2015, 36, 2212-2218.	2.2	61
402	Increased prothrombotic profile in the left atrial appendage of atrial fibrillation patients. <i>International Journal of Cardiology</i> , 2015, 185, 250-255.	1.7	15
403	Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. <i>Heart</i> , 2015, 101, 854-863.	2.9	38
404	Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. <i>European Heart Journal</i> , 2015, 36, 39-50.	2.2	65
405	First case of atypical takotsubo cardiomyopathy in a bilateral lung-transplanted patient due to acute respiratory failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 482-485.	1.0	14
406	Research ethics needs fine tuning, not rigidity: how to promote evidence in neglected patient populations by rethinking informed consent: Figure 1. <i>European Heart Journal</i> , 2015, 36, 2681-2685.	2.2	4
407	Clonal restriction and predominance of regulatory T cells in coronary thrombi of patients with acute coronary syndromes. <i>European Heart Journal</i> , 2015, 36, 1041-1048.	2.2	48
408	AV Block on Exertion: Pulmonary Sarcoidosis with Involvement of the His-Purkinje System. <i>American Journal of Medicine</i> , 2015, 128, e31-e33.	1.5	0
409	Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease. <i>European Heart Journal</i> , 2015, 36, 3392-3403.	2.2	183
410	Genetic deletion of the adaptor protein p66Shc increases susceptibility to short-term ischaemic myocardial injury via intracellular salvage pathways. <i>European Heart Journal</i> , 2015, 36, 516-526.	2.2	37
411	Renal denervation: simply trapped by complexity?. <i>European Heart Journal</i> , 2015, 36, 199-202.	2.2	67
412	Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. <i>European Heart Journal</i> , 2015, 36, 490-500.	2.2	168
413	Impact of local vascular lesions assessed with optical coherence tomography and ablation points on blood pressure reduction after renal denervation. <i>Swiss Medical Weekly</i> , 2015, 145, w14102.	1.6	4
414	Thrombus formation in the left ventricle after large myocardial infarction – assessment with cardiac magnetic resonance imaging. <i>Swiss Medical Weekly</i> , 2015, 145, w14122.	1.6	13

#	ARTICLE	IF	CITATIONS
415	Quality of Care after Acute Coronary Syndromes in a Prospective Cohort with Reasons for Non-Prescription of Recommended Medications. PLoS ONE, 2014, 9, e93147.	2.5	28
416	Alternatively Spliced Tissue Factor Is Not Sufficient for Embryonic Development. PLoS ONE, 2014, 9, e97793.	2.5	4
417	Recovery mismatch between myocardial blood flow and cardiac workload after physical exercise: a positron emission tomography study. European Heart Journal Cardiovascular Imaging, 2014, 15, 1386-1390.	1.2	0
418	Adaptor Protein p66 ^{Shc} Mediates Hypertension-Associated, Cyclic Stretch-Dependent, Endothelial Damage. Hypertension, 2014, 64, 347-353.	2.7	47
419	TAVI in a low left main coronary artery ostium and wide aortic sinus of Valsava. European Heart Journal, 2014, 35, 1791-1791.	2.2	1
420	First three-dimensional optical frequency domain imaging evaluation of a bioabsorbable vascular scaffold implantation in an instant-restenosis 6 years after CYPHER stenting. European Heart Journal, 2014, 35, 1393-1393.	2.2	0
421	Percutaneous retrieval of an endothelialized AMPLATZER cardiac plug from the abdominal aorta 6 months after embolization. European Heart Journal, 2014, 35, 3387-3387.	2.2	6
422	Continuing Medical Education Activity in Echocardiography. Echocardiography, 2014, 31, 1005-1005.	0.9	0
423	Essential role of sympathetic endothelin A receptors for adverse cardiac remodeling. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13499-13504.	7.1	30
424	Endothelial overexpression of LOX-1 increases plaque formation and promotes atherosclerosis in vivo. European Heart Journal, 2014, 35, 2839-2848.	2.2	82
425	Renal nerve ablation after SYMPPLICITY HTN-3: confused at the higher level?. European Heart Journal, 2014, 35, 1706-1711.	2.2	69
426	Clinical Criteria Replenish High-Sensitive Troponin and Inflammatory Markers in the Stratification of Patients with Suspected Acute Coronary Syndrome. PLoS ONE, 2014, 9, e98626.	2.5	10
427	Dual Role of Endothelial Nitric Oxide Synthase in Oxidized LDL-Induced, p66Shc-Mediated Oxidative Stress in Cultured Human Endothelial Cells. PLoS ONE, 2014, 9, e107787.	2.5	22
428	Characterization of Pulmonary Vein Dimensions Using High-Definition 64-Slice Computed Tomography prior to Radiofrequency Catheter Ablation for Atrial Fibrillation. Cardiology Research and Practice, 2014, 2014, 1-8.	1.1	24
429	Anti-inflammatory therapies for cardiovascular disease. European Heart Journal, 2014, 35, 1782-1791.	2.2	469
430	High-Density Lipoprotein. Circulation Research, 2014, 114, 171-182.	4.5	236
431	Carbamylated low-density lipoprotein induces endothelial dysfunction. European Heart Journal, 2014, 35, 3021-3032.	2.2	114
432	Percutaneous Mitral Valve Edge-to-Edge Repair. Journal of the American College of Cardiology, 2014, 64, 875-884.	2.8	398

#	ARTICLE	IF	CITATIONS
433	Epigenetic regulation of tissue factor inducibility in endothelial cell senescence. <i>Mechanisms of Ageing and Development</i> , 2014, 140, 1-9.	4.6	6
434	Enhanced age-dependent cerebrovascular dysfunction is mediated by adaptor protein p66Shc. <i>International Journal of Cardiology</i> , 2014, 175, 446-450.	1.7	31
435	Takotsubo cardiomyopathy: still much more to learn. <i>Heart</i> , 2014, 100, 1804-1812.	2.9	75
436	Acute multivessel revascularization improves 1-year outcome in ST-elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2014, 172, 76-81.	1.7	34
437	Usefulness of Electrocardiographic Parameters for Risk Prediction in Arrhythmogenic Right Ventricular Dysplasia. <i>American Journal of Cardiology</i> , 2014, 113, 1728-1734.	1.6	54
438	Rehabilitation after TAVI compared to surgical aortic valve replacement. <i>International Journal of Cardiology</i> , 2014, 173, 564-566.	1.7	27
439	The MI SYNTAX score for risk stratification in patients undergoing primary percutaneous coronary intervention for treatment of acute myocardial infarction: A substudy of the COMFORTABLE AMI trial. <i>International Journal of Cardiology</i> , 2014, 175, 314-322.	1.7	24
440	Two-year outcomes after percutaneous mitral valve repair with the MitraClip system: durability of the procedure and predictors of outcome. <i>Open Heart</i> , 2014, 1, e000056.	2.3	60
441	Long-Term Performance of Modern Coronary Sinus Leads in Cardiac Resynchronization Therapy. <i>Indian Pacing and Electrophysiology Journal</i> , 2014, 14, 112-120.	0.6	5
442	The Intercept Blood System Affects Platelet Function and Survival By Inducing Apoptosis. <i>Blood</i> , 2014, 124, 4283-4283.	1.4	3
443	Dietary ω -3 linolenic acid increases the platelet count in ApoE ^{-/-} mice by reducing clearance. <i>Blood</i> , 2013, 122, 1026-1033.	1.4	18
444	Cardiac hybrid imaging guides revascularization prior to non-cardiac surgery. <i>International Journal of Cardiology</i> , 2013, 163, e44-e46.	1.7	1
445	Dietary Alpha-Linolenic Acid Does Not Protect From Venous Thrombosis In The Vena Cava Stenosis Model. <i>Blood</i> , 2013, 122, 3621-3621.	1.4	0
446	Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. <i>European Heart Journal</i> , 2012, 33, 857-865.	2.2	201
447	Addition of Omega-3 ω -3 Linolenic Acid to Platelet Apheresis Units Preserves Platelet Activatability Over Time and Reduces Baseline Activation Under Routine Storage Conditions: A Pilot Study. <i>Blood</i> , 2012, 120, 3433-3433.	1.4	2
448	High-sensitivity Troponins – Difficult Friends in Acute Coronary Syndromes. <i>US Cardiology Review</i> , 2012, 9, 121-125.	0.5	0
449	Dietary ω -3 linolenic acid diminishes experimental atherogenesis and restricts T cell-driven inflammation. <i>European Heart Journal</i> , 2011, 32, 2573-2584.	2.2	56
450	SYNTAX score and Clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of SIRolimus-eluting stent compared with pacliTAXel-eluting stent for coronary revascularization (SIRTAX) trial. <i>European Heart Journal</i> , 2011, 32, 3115-3127.	2.2	136

#	ARTICLE	IF	CITATIONS
451	Analysis of the Mechanisms of Increased Platelet Count Induced by Dietary $\hat{\pm}$ -Linolenic Acid Indicates Reduced Cleavage of GPIb and Reduced p38 Phosphorylation. <i>Blood</i> , 2011, 118, 2198-2198.	1.4	1
452	Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. <i>American Heart Journal</i> , 2009, 157, 606-612.	2.7	115
453	Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. <i>European Heart Journal</i> , 2007, 28, 941-948.	2.2	178
454	Dark Chocolate Improves Coronary Vasomotion and Reduces Platelet Reactivity. <i>Circulation</i> , 2007, 116, 2376-2382.	1.6	215
455	Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. <i>Lancet, The</i> , 2007, 369, 1869-1875.	13.7	803
456	Inactivity of nitric oxide synthase gene in the atherosclerotic human carotid artery. <i>Basic Research in Cardiology</i> , 2007, 102, 308-317.	5.9	12
457	Tissue Factor in Cardiovascular Diseases. <i>Circulation</i> , 2006, 113, 722-731.	1.6	439
458	Inflammatory Markers at the Site of Ruptured Plaque in Acute Myocardial Infarction. <i>Circulation</i> , 2005, 111, 1355-1361.	1.6	255
459	The Renin-Angiotensin System, Capri 2005. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2005, 12, 91-108.	2.2	0
460	Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. <i>American Journal of Hypertension</i> , 2004, 17, S243.	2.0	0
461	Coffee Acutely Increases Sympathetic Nerve Activity and Blood Pressure Independently of Caffeine Content. <i>Circulation</i> , 2002, 106, 2935-2940.	1.6	214
462	Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ET _A) Receptor Blockade in Chronic Heart Failure. <i>Circulation</i> , 2002, 106, 2666-2672.	1.6	221
463	Effects of blood pressure and glucose on endothelial function. <i>Current Hypertension Reports</i> , 2001, 3, 79-88.	3.5	31
464	Vasopeptidase Inhibition Restores Renovascular Endothelial Dysfunction in Salt-Induced Hypertension. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2280-2287.	6.1	32
465	Autonomic Nervous System-Controlled Cardiac Pacing: A Comparison Between Intracardiac Impedance Signal and Muscle Sympathetic Nerve Activity. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2000, 23, 1632-1637.	1.2	18
466	Gene therapy at the clinical horizon?. <i>Current Hypertension Reports</i> , 2000, 2, 62-63.	3.5	0
467	Nitric oxide production by isolated human and porcine ciliary processes. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2000, 238, 448-453.	1.9	7
468	Nifedipine inhibits superoxide production induced by pulsatile stretch in human aortic endothelial cells. <i>American Journal of Hypertension</i> , 2000, 13, S34.	2.0	1

#	ARTICLE	IF	CITATIONS
469	Dysfunctional Renal Nitric Oxide Synthase as a Determinant of Salt-Sensitive Hypertension. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 835-845.	6.1	91
470	The Potential for Inappropriate Ventricular Tachycardia Confirmation Using the Intracardiac Electrogram (EGM) Width Criterion. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1999, 22, 1039-1046.	1.2	18
471	Endothelin in cardiovascular control: The role of endothelin antagonists. <i>Current Hypertension Reports</i> , 1999, 1, 79-87.	3.5	14
472	Low or High Iodine Content of Contrast Medium for Cardiac Angiography?. <i>Journal of Interventional Cardiology</i> , 1998, 11, 113-116.	1.2	2
473	Modulation of endothelin-1-induced contractions by magnesium/calcium in porcine ciliary arteries. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 1998, 236, 47-51.	1.9	30
474	Î ² -Adrenergic agonist-induced nitrite production in isolated pig ciliary processes. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 1998, 236, 613-616.	1.9	11
475	Endothelin-1 induces vasodilation in human skin by nociceptor fibres and release of nitric oxide. <i>British Journal of Clinical Pharmacology</i> , 1998, 45, 441-446.	2.4	38
476	The Classification of Calcium Antagonists and their Selection in the Treatment of Hypertension. <i>Drugs</i> , 1998, 55, 509-517.	10.9	59
477	Biology of the Endothelium. <i>Clinical Cardiology</i> , 1997, 20, II-3.	1.8	243
478	Effect of endothelin antagonists on the responses to prostanoid endothelium-derived contracting factor. <i>British Journal of Pharmacology</i> , 1996, 118, 1429-1432.	5.4	22
479	Substance P in human hand veins in vivo: Tolerance, efficacy, potency, and mechanism of venodilator action*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 435-443.	4.7	14
480	Nitric Oxide in Cardiovascular Diseases. <i>Annals of Medicine</i> , 1995, 27, 343-351.	3.8	56
481	Circadian Carbamazepine Toxicity. <i>Epilepsia</i> , 1994, 35, 400-402.	5.1	10
482	Endothelial Dysfunction in Coronary Artery Disease. <i>Annual Review of Medicine</i> , 1993, 44, 395-418.	12.2	211
483	Calcium Antagonists and ACE Inhibitors. <i>Drugs</i> , 1993, 46, 121-132.	10.9	30
484	Age, Hypertension and Hypercholesterolaemia Alter Endothelium-Dependent Vascular Regulation. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1992, 70, S32-9.	0.0	47
485	Functional Abnormalities of the Vascular Endothelium in Hypertension and Atherosclerosis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1990, 50, 28-32.	1.2	7
486	Endothelial Control of Vascular Tone and Growth. <i>Clinical and Experimental Hypertension</i> , 1990, 12, 897-902.	0.3	16

#	ARTICLE	IF	CITATIONS
487	Aging differentially affects direct and indirect actions of endothelinâ€1 in perfused mesenteric arteries of the rat. British Journal of Pharmacology, 1990, 100, 889-893.	5.4	75
488	Difference between Endothelium-Dependent Relaxation in Arterial and in Venous Coronary Bypass Grafts. New England Journal of Medicine, 1988, 319, 462-467.	27.0	524
489	Histamine. , 0, , 295-314.		1
490	Coronary stent thrombosis in acute coronary syndromes. Cardiovascular Medicine(Switzerland), 0, , .	0.0	0
491	Die Wiederauferstehung der renalen Denervation. Cardiovascular Medicine(Switzerland), 0, , .	0.0	0